3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 2,478,229 | 2,555,397 |
受取手形、売掛金及び契約資産 | 1,342,735 | 1,195,011 |
電子記録債権 | - | 22,970 |
商品及び製品 | 1,592,915 | 1,348,725 |
仕掛品 | 507,606 | 796,709 |
原材料及び貯蔵品 | 127,179 | 76,516 |
前渡金 | 287,891 | 581,812 |
その他 | 219,787 | 128,020 |
貸倒引当金 | △6,839 | △6,268 |
流動資産合計 | 6,549,505 | 6,698,896 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 1,934,052 | 2,046,742 |
減価償却累計額 | △851,207 | △976,747 |
建物及び構築物(純額) | 1,082,845 | 1,069,994 |
機械装置及び運搬具 | 131,088 | 318,857 |
減価償却累計額 | △119,869 | △261,776 |
機械装置及び運搬具(純額) | 11,218 | 57,080 |
工具、器具及び備品 | 641,468 | 566,526 |
減価償却累計額 | △514,618 | △557,510 |
工具、器具及び備品(純額) | 126,850 | 9,015 |
土地 | 896,676 | 917,473 |
その他 | 33,570 | 31,135 |
減価償却累計額 | △27,649 | △29,677 |
その他(純額) | 5,920 | 1,457 |
建設仮勘定 | 18,700 | - |
有形固定資産合計 | 2,142,211 | 2,055,021 |
無形固定資産 | | |
のれん | 512,287 | 531,780 |
ソフトウエア | 13,113 | 12,037 |
その他 | 7,609 | 10,105 |
無形固定資産合計 | 533,010 | 553,923 |
投資その他の資産 | | |
投資有価証券 | 128,593 | 107,693 |
長期貸付金 | 1,000 | 1,000 |
繰延税金資産 | 321,978 | 31,497 |
その他 | 149,851 | 148,978 |
貸倒引当金 | △15,151 | △10,612 |
投資その他の資産合計 | 586,271 | 278,557 |
固定資産合計 | 3,261,493 | 2,887,503 |
資産合計 | 9,810,999 | 9,586,399 |
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
支払手形及び買掛金 | 276,141 | 413,459 |
未払金 | 238,718 | 223,351 |
短期借入金 | 448,000 | 680,000 |
1年内償還予定の社債 | 14,000 | 14,000 |
1年内返済予定の長期借入金 | 452,733 | 524,659 |
未払法人税等 | 43,908 | 51,661 |
前受金 | 655,548 | 1,020,758 |
賞与引当金 | 71,761 | 69,688 |
受注損失引当金 | 1,661 | 61,989 |
その他 | 231,815 | 212,508 |
流動負債合計 | 2,434,288 | 3,272,076 |
固定負債 | | |
社債 | 123,000 | 109,000 |
長期借入金 | 1,184,570 | 1,247,401 |
繰延税金負債 | - | 12,921 |
退職給付に係る負債 | 37,644 | 68,774 |
その他 | 33,032 | 20,043 |
固定負債合計 | 1,378,246 | 1,458,140 |
負債合計 | 3,812,535 | 4,730,217 |
純資産の部 | | |
株主資本 | | |
資本金 | 50,000 | 50,000 |
資本剰余金 | 3,861,314 | 3,857,377 |
利益剰余金 | 2,067,097 | 927,674 |
自己株式 | △135,948 | △116,016 |
株主資本合計 | 5,842,463 | 4,719,036 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 25,959 | 18,817 |
為替換算調整勘定 | 25,461 | 24,657 |
その他の包括利益累計額合計 | 51,420 | 43,474 |
新株予約権 | 200 | 200 |
非支配株主持分 | 104,380 | 93,470 |
純資産合計 | 5,998,464 | 4,856,181 |
負債純資産合計 | 9,810,999 | 9,586,399 |
E0531723420株式会社トランスジェニックグループTRANS GENIC GROUP INC.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse234202024-03-31jppfs_cor:RetainedEarningsMember234202024-03-31jppfs_cor:CapitalSurplusMember234202024-03-31jppfs_cor:CapitalStockMember234202023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember234202023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember234202023-04-012024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember234202023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember234202023-04-012024-03-31jppfs_cor:ShareholdersEquityMember234202023-04-012024-03-31jppfs_cor:TreasuryStockMember234202023-04-012024-03-31jppfs_cor:RetainedEarningsMember234202023-04-012024-03-31jppfs_cor:CapitalSurplusMember234202023-04-012024-03-31jppfs_cor:CapitalStockMember234202023-03-31jppfs_cor:SubscriptionRightsToSharesMember234202023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember234202023-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember234202023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember234202023-03-31jppfs_cor:ShareholdersEquityMember234202023-03-31jppfs_cor:TreasuryStockMember234202023-03-31jppfs_cor:RetainedEarningsMember234202023-03-31jppfs_cor:CapitalSurplusMember234202023-03-31jppfs_cor:CapitalStockMember234202023-04-012024-03-31jppfs_cor:NonControllingInterestsMember234202025-03-31jppfs_cor:NonControllingInterestsMember234202024-04-012025-03-31jppfs_cor:NonControllingInterestsMember234202024-03-31jppfs_cor:NonControllingInterestsMember234202025-03-31jppfs_cor:SubscriptionRightsToSharesMember234202025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember234202025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember234202025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember234202025-03-31jppfs_cor:ShareholdersEquityMember234202025-03-31jppfs_cor:TreasuryStockMember234202025-03-31jppfs_cor:RetainedEarningsMember234202025-03-31jppfs_cor:CapitalSurplusMember234202025-03-31jppfs_cor:CapitalStockMember234202024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember234202024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember234202024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember234202024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember234202024-04-012025-03-31jppfs_cor:ShareholdersEquityMember234202024-04-012025-03-31jppfs_cor:TreasuryStockMember234202024-04-012025-03-31jppfs_cor:RetainedEarningsMember234202024-04-012025-03-31jppfs_cor:CapitalSurplusMember234202024-04-012025-03-31jppfs_cor:CapitalStockMember234202024-03-31jppfs_cor:SubscriptionRightsToSharesMember234202024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember234202024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember234202024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember234202024-03-31jppfs_cor:ShareholdersEquityMember234202024-03-31jppfs_cor:TreasuryStockMember234202023-03-31jppfs_cor:NonControllingInterestsMember234202025-06-16234202025-03-31234202024-04-012025-03-31234202024-03-31234202023-04-012024-03-31234202023-03-31234202025-03-31tse-acedjpfr-23420:DrugDiscoverySupportBusinessReportableSegmentsMember234202025-03-31tse-acedjpfr-23420:InvestmentsAndConsultingBusinessReportableSegmentsMember234202024-04-012025-03-31tse-acedjpfr-23420:DrugDiscoverySupportBusinessReportableSegmentsMember234202024-04-012025-03-31tse-acedjpfr-23420:InvestmentsAndConsultingBusinessReportableSegmentsMember234202024-03-31tse-acedjpfr-23420:DrugDiscoverySupportBusinessReportableSegmentsMember234202024-03-31tse-acedjpfr-23420:InvestmentsAndConsultingBusinessReportableSegmentsMember234202023-04-012024-03-31tse-acedjpfr-23420:DrugDiscoverySupportBusinessReportableSegmentsMember234202023-04-012024-03-31tse-acedjpfr-23420:InvestmentsAndConsultingBusinessReportableSegmentsMember234202025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember234202025-03-31jpcrp_cor:ReconcilingItemsMember234202024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember234202024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember234202024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember234202024-03-31jpcrp_cor:ReconcilingItemsMember234202023-04-012024-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember234202023-04-012024-03-31jpcrp_cor:ReconcilingItemsMemberiso4217:JPYxbrli:pure